title: Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.
abstract: Gastrointestinal stromal tumour resistance to treatment with imatinib occurs due to pre-existing or acquired mutations. Computed tomography and positron-emission tomography play an essential role in prompt recognition of resistance to treatment. Primary resistance to treatment, which is encountered in the first 6 months of treatment, is associated with specific mutations. Imaging of these tumours shows no anatomical or metabolic response to treatment. Secondary resistance to treatment, which develops after an initial response, is associated with a variety of mutations acquired after the start of treatment. Imaging findings of secondary resistance are of disease progression.
authors.affiliation: Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.stirumani@partners.org
authors.forename: S H
authors.initials: SH
authors.lastname: Tirumani
authors.forename: J P
authors.initials: JP
authors.lastname: Jagannathan
authors.forename: J L
authors.initials: JL
authors.lastname: Hornick
authors.forename: N H
authors.initials: NH
authors.lastname: Ramaiya
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D003287:Contrast Media; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D019788:Fluorodeoxyglucose F18; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D011743:Pyrimidines / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D003287:Contrast Media; D010879:Piperazines; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000068877:Imatinib Mesylate